Quinone derivatives isolated from the endolichenic fungus Phialocephala fortinii are Mdr1 modulators that combat azole resistance in Candida albicans
Open Access
- 21 September 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 6 (1), 33687
- https://doi.org/10.1038/srep33687
Abstract
One of the main azole-resistance mechanisms in Candida pathogens is the upregulation of drug efflux pumps, which compromises the efficacy of azoles and results in treatment failure. The combination of azole-antifungal agents with efflux pump inhibitors represents a promising strategy to combat fungal infection. High-throughput screening of 150 extracts obtained from endolichenic fungal cultures led to the discovery that the extract of Phialocephala fortinii exhibits potent activity for the reversal of azole resistance. From P. fortinii cultures, a total of 15 quinone derivatives, comprising 11 new derivatives and 4 known compounds, were obtained. Among these compounds, palmarumycin P3 (3) and phialocephalarin B (8) specifically modulate the expression of MDR1 to inhibit the activity of drug efflux pumps and therefore reverse azole resistance. The present study revealed Mdr1 targeting as an alternative mechanism for the discovery of new agents to fight antifungal drug resistance.This publication has 56 references indexed in Scilit:
- The Monoamine Oxidase A Inhibitor Clorgyline Is a Broad-Spectrum Inhibitor of Fungal ABC and MFS Transporter Efflux Pump Activities Which Reverses the Azole Resistance of Candida albicans and Candida glabrata Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2012
- Regulation of Efflux Pump Expression and Drug Resistance by the Transcription Factors Mrr1, Upc2, and Cap1 in Candida albicansAntimicrobial Agents and Chemotherapy, 2011
- Cross‐species discovery of syncretic drug combinations that potentiate the antifungal fluconazoleMolecular Systems Biology, 2011
- ABC Transporter Cdr1p Contributes More than Cdr2p Does to Fluconazole Efflux in Fluconazole-Resistant Candida albicans Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2008
- Natural products in drug discoveryDrug Discovery Today, 2008
- Mutations in the multi‐drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole‐resistant Candida albicans strainsMolecular Microbiology, 2008
- High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infectionsProceedings of the National Academy of Sciences of the United States of America, 2007
- The evolving role of natural products in drug discoveryNature Reviews Drug Discovery, 2005
- Natural Products as Sources of New Drugs over the Period 1981−2002Journal of Natural Products, 2003
- A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow TransplantationNew England Journal of Medicine, 1992